PE41495A1 - N-alquilcarboxilatos de piperidinilo 3,4,4-trisustituidos e intermedios - Google Patents
N-alquilcarboxilatos de piperidinilo 3,4,4-trisustituidos e intermediosInfo
- Publication number
- PE41495A1 PE41495A1 PE1994256135A PE25613594A PE41495A1 PE 41495 A1 PE41495 A1 PE 41495A1 PE 1994256135 A PE1994256135 A PE 1994256135A PE 25613594 A PE25613594 A PE 25613594A PE 41495 A1 PE41495 A1 PE 41495A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- compound
- alkyl
- trisustituted
- piperidinyl
- Prior art date
Links
- -1 PIPERIDINYL Chemical class 0.000 title 1
- 150000007942 carboxylates Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002131 composite material Substances 0.000 abstract 2
- 230000007062 hydrolysis Effects 0.000 abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract 2
- FPBCFLJRIIYPPT-UHFFFAOYSA-N OCl.CC(C)=O Chemical compound OCl.CC(C)=O FPBCFLJRIIYPPT-UHFFFAOYSA-N 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000004683 dihydrates Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940049920 malate Drugs 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/164,074 US5434171A (en) | 1993-12-08 | 1993-12-08 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE41495A1 true PE41495A1 (es) | 1995-11-28 |
Family
ID=22592858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1994256135A PE41495A1 (es) | 1993-12-08 | 1994-12-01 | N-alquilcarboxilatos de piperidinilo 3,4,4-trisustituidos e intermedios |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5434171A (enExample) |
| EP (3) | EP0657428B1 (enExample) |
| JP (2) | JP3834075B2 (enExample) |
| KR (1) | KR100356239B1 (enExample) |
| CN (2) | CN1057294C (enExample) |
| AT (1) | ATE200279T1 (enExample) |
| AU (1) | AU681198B2 (enExample) |
| BR (1) | BR9404842A (enExample) |
| CA (1) | CA2137221C (enExample) |
| CO (1) | CO4290427A1 (enExample) |
| CZ (1) | CZ290559B6 (enExample) |
| DE (1) | DE69427017T2 (enExample) |
| DK (1) | DK0657428T3 (enExample) |
| ES (1) | ES2155844T3 (enExample) |
| FI (2) | FI106455B (enExample) |
| GR (1) | GR3036136T3 (enExample) |
| HU (1) | HUT71489A (enExample) |
| IL (1) | IL111843A (enExample) |
| MY (1) | MY121543A (enExample) |
| NO (1) | NO302884B1 (enExample) |
| NZ (1) | NZ270039A (enExample) |
| PE (1) | PE41495A1 (enExample) |
| PL (1) | PL181734B1 (enExample) |
| PT (1) | PT657428E (enExample) |
| RU (1) | RU2145958C1 (enExample) |
| SI (1) | SI0657428T1 (enExample) |
| TW (1) | TW290540B (enExample) |
| UA (1) | UA52577C2 (enExample) |
| YU (2) | YU49312B (enExample) |
| ZA (1) | ZA949584B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722497B1 (fr) * | 1994-07-13 | 1996-08-14 | Synthelabo | Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| GB9912416D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912410D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912415D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912417D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912413D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| EP1404323B1 (en) * | 2001-06-05 | 2009-10-28 | The University of Chicago | Use of methylnaltrexone to treat immune suppression |
| US20030068829A1 (en) * | 2001-06-25 | 2003-04-10 | Symyx Technologies, Inc. | High throughput crystallographic screening of materials |
| EP1436012B1 (en) * | 2001-10-18 | 2017-12-20 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
| US6794510B2 (en) * | 2002-08-08 | 2004-09-21 | Adolor Corporation | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto |
| US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| ES2528631T3 (es) | 2003-04-08 | 2015-02-11 | Progenics Pharmaceuticals, Inc. | Formulaciones farmacéuticas que contienen metilnaltrexona |
| CA2521369A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| FR2861304B1 (fr) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
| US20050148630A1 (en) * | 2003-12-02 | 2005-07-07 | Carpenter Randall L. | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction |
| US8946262B2 (en) * | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| KR101168620B1 (ko) | 2003-12-16 | 2012-08-03 | 넥타르 테라퓨틱스 | Ｐｅｇ화된 소분자 |
| US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| US7087749B2 (en) * | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| US20050240177A1 (en) * | 2004-04-26 | 2005-10-27 | Packaging Service Corporation Of Kentucky | Electrosurgical forceps |
| US7700626B2 (en) | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
| CN100579373C (zh) * | 2004-06-04 | 2010-01-13 | 阿得罗公司 | 包含鸦片样物质拮抗剂的组合物 |
| JP2008509930A (ja) * | 2004-08-12 | 2008-04-03 | サファイア セラピューティクス インコーポレイテッド | 成長ホルモン分泌促進物質を利用して胃腸系の運動性を刺激する方法 |
| US8039456B2 (en) | 2004-08-12 | 2011-10-18 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using ipamorelin |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| US20060211733A1 (en) * | 2005-03-04 | 2006-09-21 | Adolor Corporation | Methods of preventing and treating opioid bowel dysfunction |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) * | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| WO2007005845A1 (en) * | 2005-07-01 | 2007-01-11 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| US7914776B2 (en) * | 2005-10-07 | 2011-03-29 | Adolor Corporation | Solid dispersions of opioid antagonists |
| US20070092576A1 (en) * | 2005-10-20 | 2007-04-26 | Adolor Corporation | Compositions containing opioid antagonists |
| US7538110B2 (en) * | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| CN100383121C (zh) * | 2006-03-07 | 2008-04-23 | 天津泰普药品科技发展有限公司 | 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺 |
| WO2007121916A2 (en) | 2006-04-21 | 2007-11-01 | Dsm Ip Assets B.V. | Use of opioid receptor antagonists |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| MX2009005462A (es) * | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | Analogos de 7,8-saturados-4,5-epoxi-morfinano. |
| ES2765811T5 (es) | 2007-03-29 | 2024-02-27 | Progenics Pharm Inc | Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos |
| PL2565195T3 (pl) | 2007-03-29 | 2015-10-30 | Wyeth Llc | Obwodowy receptor opioidowy i jego antagoniści oraz ich zastosowania |
| WO2008121348A2 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| EP2730578A1 (en) | 2008-02-06 | 2014-05-14 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnal trexone |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| US8637466B2 (en) | 2008-08-11 | 2014-01-28 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| CN101429154B (zh) * | 2008-11-14 | 2011-01-05 | 天津泰普药品科技发展有限公司 | 无水阿维莫泮及其药物组合物 |
| US20100311782A1 (en) | 2009-06-08 | 2010-12-09 | Adolor Corporation | Substituted piperidinylpropanoic acid compounds and methods of their use |
| HRP20191029T1 (hr) | 2009-12-04 | 2019-09-20 | Alkermes Pharma Ireland Limited | Derivati morfinana radi liječenja predoziranja lijekom |
| WO2011161646A2 (en) | 2010-06-25 | 2011-12-29 | Ranbaxy Laboratories Limited | Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
| CN103360302B (zh) * | 2012-03-29 | 2015-08-26 | 北大方正集团有限公司 | 阿维莫泮的纯化方法 |
| US10314839B2 (en) | 2014-10-20 | 2019-06-11 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| US9808452B2 (en) | 2015-10-01 | 2017-11-07 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| AU2018234911B2 (en) | 2017-03-17 | 2024-04-18 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| WO2024090512A1 (ja) * | 2022-10-27 | 2024-05-02 | 株式会社京都創薬研究所 | ナフタレン誘導体の結晶 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891379A (en) * | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
| US5136040A (en) * | 1991-02-26 | 1992-08-04 | Eli Lilly And Company | Preparation of substituted tetrahydropyridines |
| US5250542A (en) * | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| NZ242117A (en) * | 1991-03-29 | 1994-11-25 | Lilly Co Eli | 4-phenylpiperidine derivatives and medicaments containing them |
| US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
-
1993
- 1993-12-08 US US08/164,074 patent/US5434171A/en not_active Expired - Lifetime
-
1994
- 1994-12-01 PL PL94306068A patent/PL181734B1/pl not_active IP Right Cessation
- 1994-12-01 PE PE1994256135A patent/PE41495A1/es not_active Application Discontinuation
- 1994-12-01 IL IL11184394A patent/IL111843A/xx not_active IP Right Cessation
- 1994-12-01 AU AU79170/94A patent/AU681198B2/en not_active Ceased
- 1994-12-01 TW TW083111189A patent/TW290540B/zh not_active IP Right Cessation
- 1994-12-01 CZ CZ19942992A patent/CZ290559B6/cs not_active IP Right Cessation
- 1994-12-01 JP JP29835694A patent/JP3834075B2/ja not_active Expired - Fee Related
- 1994-12-01 NZ NZ270039A patent/NZ270039A/en not_active IP Right Cessation
- 1994-12-01 ZA ZA949584A patent/ZA949584B/xx unknown
- 1994-12-02 YU YU70294A patent/YU49312B/sh unknown
- 1994-12-02 AT AT94308951T patent/ATE200279T1/de not_active IP Right Cessation
- 1994-12-02 NO NO944644A patent/NO302884B1/no not_active IP Right Cessation
- 1994-12-02 EP EP94308951A patent/EP0657428B1/en not_active Expired - Lifetime
- 1994-12-02 SI SI9430367T patent/SI0657428T1/xx unknown
- 1994-12-02 PT PT94308951T patent/PT657428E/pt unknown
- 1994-12-02 RU RU94042903A patent/RU2145958C1/ru not_active IP Right Cessation
- 1994-12-02 CA CA2137221A patent/CA2137221C/en not_active Expired - Fee Related
- 1994-12-02 YU YU82304A patent/YU82304A/sh unknown
- 1994-12-02 ES ES94308951T patent/ES2155844T3/es not_active Expired - Lifetime
- 1994-12-02 HU HU9403466A patent/HUT71489A/hu unknown
- 1994-12-02 DK DK94308951T patent/DK0657428T3/da active
- 1994-12-02 FI FI945703A patent/FI106455B/fi not_active IP Right Cessation
- 1994-12-02 BR BR9404842A patent/BR9404842A/pt not_active Application Discontinuation
- 1994-12-02 CO CO94055028A patent/CO4290427A1/es unknown
- 1994-12-02 EP EP99203390A patent/EP0984004A3/en not_active Withdrawn
- 1994-12-02 DE DE69427017T patent/DE69427017T2/de not_active Expired - Lifetime
- 1994-12-02 UA UA94129124A patent/UA52577C2/uk unknown
- 1994-12-02 EP EP05077072A patent/EP1607387A3/en not_active Withdrawn
- 1994-12-03 CN CN94119376A patent/CN1057294C/zh not_active Expired - Fee Related
- 1994-12-05 MY MYPI94003238A patent/MY121543A/en unknown
- 1994-12-05 KR KR1019940032794A patent/KR100356239B1/ko not_active Expired - Fee Related
-
1998
- 1998-12-03 CN CN98123069A patent/CN1121387C/zh not_active Expired - Fee Related
-
2000
- 2000-02-17 FI FI20000353A patent/FI106860B/fi not_active IP Right Cessation
-
2001
- 2001-06-27 GR GR20010400990T patent/GR3036136T3/el not_active IP Right Cessation
-
2005
- 2005-10-18 JP JP2005303195A patent/JP2006070042A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE41495A1 (es) | N-alquilcarboxilatos de piperidinilo 3,4,4-trisustituidos e intermedios | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| LU91069I2 (fr) | Aprepitant et ses sels pharmaceutiquement acceptables (EMEND) | |
| TW357146B (en) | Tetrahydrofuran antifungals | |
| ZA9710255B (en) | Crystals of benzimidazole derivatives and their production | |
| PE1998A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
| PE110899A1 (es) | Derivados de acidos ariloxiarilsulfonilamino hidroxamicos | |
| EA200200510A1 (ru) | 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр | |
| RU94027560A (ru) | Борат цинка, кристаллический гидратированный борат цинка и способы его получения, композиция | |
| BR9704998A (pt) | Dispersões de agentes de branqueamento fluorescente | |
| ATE374773T1 (de) | Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten | |
| PT731788E (pt) | Inibidores de prolil endopeptidase | |
| AU1703901A (en) | Stain and soil removal in the laundering of textile fabrics | |
| ATE377000T1 (de) | 5-ht1f agonisten | |
| HRP20041141A2 (en) | Method for brightening textile materials | |
| NO20013832L (no) | Piperidin- og piperazinderivater som hemmere ved Abeta-fibril- dannelsen | |
| NO980643L (no) | Propylendopeptidase inhibitorer | |
| DE60041001D1 (de) | Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien | |
| AP2004003084A0 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors | |
| CO4950614A1 (es) | Antagonistas de taquiquinina | |
| NO940265L (no) | Fremgangsmaate ved fremstilling av svovelholdige karboksyl-syreamider | |
| IL95727A0 (en) | Substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis | |
| PE34195A1 (es) | Composicion blanqueadora de hipoclorito | |
| UY28618A1 (es) | Nuevos indoles sustituidos de piperidina o heteroderivados de los mismos | |
| CA2309485A1 (en) | New 4-arylpiperidine derivatives for the treatment of pruritus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |